ENTITY
Hisamitsu Pharmaceutical Co

Hisamitsu Pharmaceutical Co (4530 JP)

86
Analysis
Health Care • Japan
HISAMITSU PHARMACEUTICAL CO., INC. produces and sells pharmaceutical products. The Company's main product is anti-inflammatory analgesic plasters and poultices sold under the brand name Salonpas. Hisamitsu Pharmaceutical exports its products to North America and Southeast Asia. The Company also researches and develops antibacterial products through its related company, RRF.
more
•05 Feb 2015 16:01

Introducing Long Term Leaders - Focussed Insights for your Core Holdings

We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...

Logo
497 Views
Share
bullish•Dongfeng Motor
•08 Mar 2026 06:19

Asia-Pac M&A Weekly Wrap: Insignia Financial, Ferretti SpA, Bright Smart Securities, Echo Marketing

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
385 Views
Share
bullish•MCJ Co Ltd
•02 Mar 2026 06:15

Asia-Pac M&A, Feb 2026 Wrap: MCJ, Magnetic Res, Inforich, Pepper Money, Takara Bio, Qoria

For the month of Feb 2026, 12 new deals were discussed on Smartkarma with an overall deal size of just ~US$7bn. The average premium for the new...

Logo
344 Views
Share
bullish•Douzone Bizon
•01 Mar 2026 06:20

Asia-Pac M&A Weekly Wrap: Douzone Bizon, Clearview Wealth, Qoria, Insignia, Humm, Mandom, Raksul

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
428 Views
Share
bearish•Yomeishu Seizo
•25 Feb 2026 21:45

Yomeishu Seizo (2540 JP): Murakami’s Takeunder Is Self-Financing and a Done Deal

While the offer is marginally higher than KKR's offer (the highest received in an auction), the transaction's economics favour Murakami vs...

Logo
356 Views
Share
x